Publications en collaboration avec des chercheurs de Hospital Regional Universitario de Málaga (15)

2019

  1. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278

2018

  1. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients

    AIDS, Vol. 32, Núm. 11, pp. 1423-1430

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255

  2. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

  3. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial

    Clinical Infectious Diseases, Vol. 60, Núm. 11, pp. 1642-1649

2014

  1. Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population

    PLoS ONE, Vol. 9, Núm. 5

2009

  1. Efficacy and safely of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression

    Clinical Infectious Diseases, Vol. 49, Núm. 8

2008

  1. Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373

2006

  1. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 6, pp. 373-378

2005

  1. Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 10, pp. 581-585

  2. Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors

    Quality of Life Research, Vol. 14, Núm. 5, pp. 1301-1310

  3. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study

    HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328

1998

  1. Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin

    Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525